Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

knowledge about and faith in the treatment, effective patient-clinician interaction, and routinization of drug therapy are critical for optimal medication adherence in patients with COPD.

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

The CRYSTAL trial is the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with moderate COPD from their current treatments.

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

"This may inform prescribing of glucose-lowering medications among ... follow-up spanned 145 days of treatment. For the primary endpoint of moderate or severe COPD exacerbation, defined as a ...

This may inform prescribing of glucose-lowering medications among patients with type 2 diabetes and active COPD.

St. Vincent’s Riverside is now offering a breakthrough treatment for patients diagnosed with chronic pulmonary obstructive disease (COPD)/emphysema. COPD affects the lungs and their ability to ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

“This could influence treatment decisions and improve respiratory health in this high-risk population.” “GLP-1 medications might help lower COPD exacerbation risk by reducing systemic ...